
@emcs_tecdemty md’25 | Former research intern @incanmx | Postdoc research fellow at @MDAndersonNews 🧫| op = own |
- Tweets3.9K
- Following830
- Followers1.6K
- Likes12.1K

ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.

ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.



































